deltatrials
Completed PHASE1 INTERVENTIONAL 2-arm NCT02950259

Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)

A Phase Ib Study to Assess the Safety, Tolerability and Immunologic Activity of Preoperative IRX 2 In Early Stage Breast Cancer

Sponsor: Brooklyn ImmunoTherapeutics, LLC

Conditions Breast Neoplasm Breast Neoplasm, Male Triple Negative Breast Cancer
Interventions Cyclophosphamide Indomethacin Multivitamin Omeprazole
Updated 15 times since 2017 Last updated: Nov 17, 2025 Started: Feb 9, 2017 Primary completion: May 13, 2019 Completion: Sep 25, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02950259, this PHASE1 trial focuses on Breast Neoplasm and Breast Neoplasm, Male and remains completed. Sponsored by Brooklyn ImmunoTherapeutics, LLC, it has been updated 15 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~Jan 2018 · 10 months · monthly snapshot~Jan 2018 – ~Jun 2018 · 5 months · monthly snapshot~Jun 2018 – ~Jan 2019 · 7 months · monthly snapshot~Jan 2019 – ~Oct 2019 · 9 months · monthly snapshot~Oct 2019 – ~Jan 2021 · 15 months · monthly snapshot~Jan 2021 – ~Oct 2021 · 9 months · monthly snapshot~Oct 2021 – ~Mar 2022 · 5 months · monthly snapshot~Mar 2022 – ~Feb 2024 · 23 months · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Apr 2025 · 7 months · monthly snapshot~Apr 2025 – ~Jan 2026 · 9 months · monthly snapshot~Jan 2026 – present · 5 months · monthly snapshot

Change History

15 versions recorded

  1. Jan 2026 — Present [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  2. Apr 2025 — Jan 2026 [monthly]

    Active Not Recruiting PHASE1

  3. Sep 2024 — Apr 2025 [monthly]

    Active Not Recruiting PHASE1

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1

  5. Feb 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1

▶ Show 10 earlier versions

  1. Mar 2022 — Feb 2024 [monthly]

    Active Not Recruiting PHASE1

    Status: Unknown Status → Active Not Recruiting

  2. Oct 2021 — Mar 2022 [monthly]

    Unknown Status PHASE1

    Status: Active Not Recruiting → Unknown Status

  3. Jan 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE1

  4. Oct 2019 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

  5. Jan 2019 — Oct 2019 [monthly]

    Active Not Recruiting PHASE1

  6. Jun 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  7. Jan 2018 — Jun 2018 [monthly]

    Recruiting PHASE1

  8. Mar 2017 — Jan 2018 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  9. Feb 2017 — Mar 2017 [monthly]

    Not Yet Recruiting PHASE1

  10. Jan 2017 — Feb 2017 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Brooklyn ImmunoTherapeutics, LLC
  • Providence Health & Services
Data source: Providence Health & Services

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations